Key result
Macitentan is linked to ~63% greater treatment persistence versus bosentan in PAH.
Why the study?
Real-world data on the comparative effectiveness of endothelin receptor antagonists for pulmonary arterial hypertension are scarce, particularly in Asian countries.
Does macitentan improve treatment persistence compared to ambrisentan and bosentan in Japanese patients with pulmonary arterial hypertension?
Observational (n=910)
Yes
Does macitentan improve treatment persistence compared to ambrisentan and bosentan in Japanese patients with pulmonary arterial hypertension?
Real-world data from Japan indicates that macitentan has significantly higher treatment persistence compared to ambrisentan and bosentan in patients with pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
May favor macitentan for persistence in Japanese PAH; hypothesis-generating and requires prospective confirmation.
INTRODUCTION: Real-world data on the comparative effectiveness of endothelin receptor antagonists (ERAs; macitentan, bosentan, ambrisentan) for pulmonary arterial hypertension (PAH), particularly in Asian countries, are scarce. We evaluated the persistence of these ERAs before and after macitentan approval in Japan (2015). METHODS: We used real-world data from the Japanese Medical Data Vision administrative claims database between April 2008 and November 2020. Patients with PAH were identified from the dataset. Persistence to ERA treatment before and after approval of macitentan in Japan was defined as the time between start of the index ERA and treatment discontinuation or death. Propensity score adjustment was applied to minimize confounding effects among treatment groups. RESULTS: In the pre-macitentan approval cohort, 153 and 51 patients received bosentan and ambrisentan, respectively. In the post-macitentan approval cohort, 331, 284, and 91 patients received macitentan, bosentan, and ambrisentan, respectively. Unadjusted median persistence for ambrisentan- and bosentan-treated patients was 19 and 10 months, respectively (adjusted HR 0.87 [95% CI 0.61-1.24]; P = 0.434 [bosentan as reference]). In the post-macitentan approval cohort, unadjusted median persistence was 18 months for macitentan-treated patients versus 6 and 8 months for ambrisentan- and bosentan-treated patients, respectively. Adjusted HRs for ambrisentan and bosentan were 1.48 (95% CI 1.12-1.95; P = 0.006) and 1.63 (95% CI 1.30-2.04; P < 0.001 [macitentan as reference]), respectively. CONCLUSIONS: Real-world data for Japanese patients with PAH showed that persistence was significantly higher for macitentan, versus ambrisentan and bosentan, since its approval.
No takes yet. Share an insight, caveat, or question.
Omura et al. (2023) conducted an observational in Pulmonary Arterial Hypertension (n=910). Macitentan vs. Bosentan and Ambrisentan was evaluated on Persistence to ERA treatment (time to treatment discontinuation or death) (HR 1.63, 95% CI 1.30-2.04, p=<0.001). Macitentan demonstrated higher treatment persistence compared to bosentan and ambrisentan in Japanese patients with pulmonary arterial hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: